Antje Prasse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5906639/publications.pdf

Version: 2024-02-01

145 papers	7,622 citations	61984 43 h-index	56724 83 g-index
157 all docs	157 docs citations	157 times ranked	8812 citing authors

#	Article	IF	Citations
1	Sarcoidosis. Lancet, The, 2014, 383, 1155-1167.	13.7	900
2	A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 781-792.	5.6	403
3	Circulating CD21^{low}B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13451-13456.	7.1	308
4	Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7853-7858.	7.1	306
5	Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 717-723.	5.6	290
6	Alternatively activated alveolar macrophages in pulmonary fibrosisâ€"mediator production and intracellular signal transduction. Clinical Immunology, 2010, 137, 89-101.	3.2	268
7	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	10.7	254
8	The pathogenesis of pulmonary fibrosis: a moving target. European Respiratory Journal, 2013, 41, 1207-1218.	6.7	252
9	CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 1685-1693.	6.7	202
10	Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 578-585.	5.6	198
11	Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0116775.	2.5	170
12	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	6.7	148
13	Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 540-548.	5.6	146
14	Phenotypes of organ involvement in sarcoidosis. European Respiratory Journal, 2018, 51, 1700991.	6.7	146
15	Phenotyping Sarcoidosis from a Pulmonary Perspective. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 330-336.	5.6	137
16	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	3.6	135
17	BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 622-630.	5.6	121
18	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respiratory Medicine,the, 2017, 5, 857-868.	10.7	115

#	Article	IF	Citations
19	Whole-Blood Flow-Cytometric Analysis of Antigen-Specific CD4 T-Cell Cytokine Profiles Distinguishes Active Tuberculosis from Non-Active States. PLoS ONE, 2011, 6, e17813.	2.5	109
20	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	6.7	102
21	Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. PLoS ONE, 2013, 8, e81382.	2.5	102
22	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	2.0	94
23	Nontransformed, GM-CSFâ€“dependent macrophage lines are a unique model to study tissue macrophage functions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2191-8.	7.1	91
24	Sarcoidosis: a review for the internist. Internal and Emergency Medicine, 2018, 13, 325-331.	2.0	88
25	Sarcoidosis-Immunopathogenetic Concepts. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 003-014.	2.1	86
26	Safety and Efficacy of an Inhaled Epidermal Growth Factor Receptor Inhibitor (BIBW 2948 BS) in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 438-445.	5.6	82
27	Immunologic Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 390-403.	2.1	82
28	Genetics of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 391-414.	2.1	80
29	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respiratory Research, 2019, 20, 59.	3.6	73
30	The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis. Deutsches Ärzteblatt International, 2016, 113, 565-74.	0.9	72
31	Nonâ€invasive biomarkers in pulmonary fibrosis. Respirology, 2009, 14, 788-795.	2.3	68
32	Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2013, 19, 503-509.	2.6	66
33	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	10.7	65
34	Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis. PLoS ONE, 2016, 11, e0147258.	2.5	63
35	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe, The, 2021, 2, e300-e310.	7.3	60
36	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology, 2009, 174, 1683-1691.	3.8	59

#	Article	IF	Citations
37	A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls. Proteomics - Clinical Applications, 2014, 8, 932-950.	1.6	57
38	Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis. Inflammation, 2020, 43, 1-7.	3.8	56
39	IL-10â€“producing monocytes differentiate to alternatively activated macrophages and areÂincreased in atopic patients. Journal of Allergy and Clinical Immunology, 2007, 119, 464-471.	2.9	55
40	Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. European Respiratory Journal, 2014, 43, 1530-1532.	6.7	54
41	Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Molecular Medicine, 2021, 13, e12871.	6.9	53
42	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration, 2016, 92, 98-106.	2.6	52
43	The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation. European Respiratory Journal, 2020, 55, 1900119.	6.7	51
44	C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal Pneumonia. PLoS Pathogens, 2016, 12, e1006038.	4.7	51
45	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
46	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. European Respiratory Journal, 2016, 48, 92-103.	6.7	46
47	Pathogenesis of sarcoidosis. Presse Medicale, 2012, 41, e275-e287.	1.9	44
48	CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respiratory Research, 2005, 6, 75.	3.6	43
49	Impairment of Immunoproteasome Function by Cigarette Smoke and in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1230-1241.	5.6	42
50	Immune response to Propionibacterium acnes in patients with sarcoidosis â€“ in vivo and in vitro. BMC Pulmonary Medicine, 2015, 15, 75.	2.0	37
51	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 370-380.	5.7	37
52	Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly. PLoS ONE, 2015, 10, e0126357.	2.5	33
53	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	2.6	33
54	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PLoS ONE, 2017, 12, e0180859.	2.5	33

#	Article	IF	Citations
55	Calgranulin B (S100A9/MRP14): A Key Molecule in Idiopathic Pulmonary Fibrosis?. Inflammation, 2011, 34, 85-91.	3.8	32
56	The EvA study: aims and strategy. European Respiratory Journal, 2012, 40, 823-829.	6.7	29
57	Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 749-757.	2.9	29
58	MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis. Journal of Biological Chemistry, 2019, 294, 5008-5022.	3.4	29
59	Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. European Respiratory Journal, 2021, 58, 2002950.	6.7	29
60	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	5.6	29
61	CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cellular Signalling, 2020, 73, 109672.	3.6	28
62	The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells. Frontiers in Immunology, 2021, 12, 642855.	4.8	27
63	The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respiratory Medicine, 2011, 105, 122-129.	2.9	26
64	Transcriptome profiles in sarcoidosis and their potential role in disease prediction. Current Opinion in Pulmonary Medicine, 2017, 23, 487-492.	2.6	26
65	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	6.4	26
66	The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis. Thorax, 2019, 74, 947-957.	5.6	24
67	Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Frontiers in Medicine, 2020, 7, 601279.	2.6	24
68	Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor. European Journal of Internal Medicine, 2020, 78, 58-62.	2.2	23
69	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 1094-1106.	0.8	23
70	Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	21
71	Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. Journal of Clinical Medicine, 2020, 9, 1567.	2.4	21
72	Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases. Journal of Trace Elements in Medicine and Biology, 2017, 42, 39-44.	3.0	19

#	Article	IF	Citations
73	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2018, 24, 2277-2284.	2.0	19
74	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	2.6	19
75	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of Clinical Medicine, 2020, 9, 1940.	2.4	18
76	OUP accepted manuscript. Rheumatology, 2019, 58, 165-178.	1.9	18
77	CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers. Inflammation, 2009, 32, 163-168.	3.8	16
78	Bronchoalveolar lavage cytology resembles sarcoidosis in a subgroup of granulomatous CVID. European Respiratory Journal, 2014, 43, 922-924.	6.7	16
79	The Analysis of Tryptase in Serum of Sarcoidosis Patients. Inflammation, 2009, 32, 310-314.	3.8	15
80	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care and Research, 2013, 65, 281-287.	3.4	15
81	CCL18 â€" Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis. Journal of Rheumatology, 2012, 39, 1407-1412.	2.0	14
82	Gene Network Analysis of Interstitial Macrophages After Treatment with Induced Pluripotent Stem Cells Secretome (iPSC-cm) in the Bleomycin Injured Rat Lung. Stem Cell Reviews and Reports, 2018, 14, 412-424.	5.6	14
83	Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma. Respirology, 2008, 13, 1022-1027.	2.3	12
84	Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease. Frontiers in Immunology, 2020, 11, 616832.	4.8	12
85	Quantification of dual-energy CT-derived functional parameters as potential imaging markers for progression of idiopathic pulmonary fibrosis. European Radiology, 2021, 31, 6640-6651.	4.5	12
86	Managing Granulomatousâ€“Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology, 2020, 11, 606333.	4.8	10
87	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosisâ€"Part B. Journal of Clinical Medicine, 2020, 9, 1993.	2.4	10
88	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
89	A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2019, 5, 151-163.	2.2	9
90	Fatal adult-onset antibody deficiency syndrome in a patient with cartilage hair hypoplasia. Human Immunology, 2010, 71, 916-919.	2.4	8

#	Article	IF	Citations
91	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1900539.	6.7	8
92	Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways. International Journal of Molecular Sciences, 2021, 22, 5696.	4.1	8
93	Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes. Scientific Reports, 2021, 11, 12848.	3.3	8
94	BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact. Chest, 2022, 161, 1576-1588.	0.8	8
95	Role of endothelial microRNA 155 on capillary leakage in systemic inflammation. Critical Care, 2021, 25, 76.	5.8	7
96	CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 3913-3918.	1.1	6
97	Granulomatousâ€“lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Research, 2021, 7, 00467-2021.	2.6	6
98	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?. PLoS ONE, 2017, 12, e0185350.	2.5	5
99	Immunomodulation in Autoimmune Interstitial Lung Disease. Respiration, 2020, 99, 819-829.	2.6	4
100	Increased regional ventilation as early imaging marker for future disease progression of interstitial lung disease: a feasibility study. European Radiology, 2022, 32, 6046-6057.	4.5	4
101	Eosinophilic cationic protein in bronchoalveolar lavage fluid of lung transplant patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 563-4.	2.3	3
102	Presence of Antibodies Binding to Negative Elongation Factor E in Sarcoidosis. Journal of Clinical Medicine, 2020, 9, 715.	2.4	3
103	Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. , 2019, , .		3
104	POINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? Yes. Chest, 2019, 156, 203-205.	0.8	2
105	Effects of a 3-week pulmonary rehabilitation program in patients with idiopathic pulmonary fibrosis â€“ A randomized, controlled trial. , 2016, , .		2
106	Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry. , 2016, , .		2
107	BAL cell transcriptome predicts survival in IPF and can be used to gauge and model treatment effects interfering with the TGF-beta pathway. , 2018, , .		2
108	Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany. , 2018, , .		2

#	Article	IF	Citations
109	Treating sarcoidosis and potential new drugs. , 2022, , 328-336.		2
110	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. Scientific Reports, 2019, 9, 20158.	3.3	1
111	Genetic Profiles of Clinical Features in Sarcoidosis. , 2018, , .		1
112	A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment. , 2018, , .		1
113	Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry. , 2019, , .		1
114	Single Cell RNA Sequencing profiles Distinct BAL Cell Subpopulations in Sarcoidosis. , 2019, , .		1
115	The Transciptome of BAL Cells at Acute Exacerbation of IPF reveals New Insights. , 2019, , .		1
116	Acute exacerbations. , 0, , 143-150.		1
117	Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. , 2020, , .		1
118	Peripheral Mucosa-homing T Cells In Fibrosis Patients Preferentially Release Th2 Cytokines. , 2010, , .		0
119	M2 Marker Expression By Alveolar Macrophages Predicts Survival In IPF. , 2010, , .		0
120	Increase In Inflammasome Activation Of Alveolar Macrophages In Pulmonary Fibrosis. , 2011, , .		0
121	â€œSarcoidosis: Recent Advancesâ€• Seminars in Respiratory and Critical Care Medicine, 2014, 35, 283-284.	2.1	0
122	Rebuttal From Dr Prasse. Chest, 2019, 156, 208-209.	0.8	0
123	Immunmodulation bei autoimmunen interstitiellen Lungenerkrankungen. Karger Kompass Autoimmun, 2021, 3, 2-9.	0.0	0
124	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0
125	Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4660-4660.	1.4	0
126	Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 1266-1266.	1.4	0

#	Article	IF	Citations
127	Biomarkers. , 2013, , 90-95.		0
128	GranulomatÃ¶se Erkrankungen. , 2016, , 169-184.		0
129	Interstitielle Lungenerkrankung bei CVID. , 2016, , 277-281.		0
130	LSC Abstract â€“ Network analysis of induced pluripotent stem cells secretome reveales its anti fibrotic action in rat lung injury model. , 2016, , .		0
131	LATE-BREAKING ABSTRACT: Molecular imaging with CXCR4-gallium-68-pentixafor PET correlates with GAP index and treatment effects in idiopathic pulmonary fibrosis. , 2016, , .		0
132	LSC Abstract â€“ Network analysis of induced pluripotent stem cells secretome reveales its anti fibrotic action in rat lung injury model. , 2016, , .		0
133	Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP). , 2016, , .		0
134	In Reply. Deutsches Ärzteblatt International, 2017, 114, 120.	0.9	0
135	Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. , 2017, , .		0
136	Transcriptional Profiling reveals Reprogramming of Airway Basal Cells in IPF. , 2017, , .		0
137	Gender associated Differences in Patients with IPF based on the Analysis of the INSIGHTS-IPF Registry Data. , 2017, , .		0
138	Transciptomic Profile TGF-Î² Inhibitor Treatment in BAL Cells from IPF Patients. Pneumologie, 2019, 73, .	0.1	0
139	Serum CCL18 Levels Predict Survival and Disease Progression in IPF Patients Treated with Antifibrotic Drugs. , 2019, 73, .		0
140	Key Role of HDAC6 Overexpression in the Migration, Proliferation and Fibrotic Remodelling by Airway Basal Cells. , 2019, 73, .		0
141	Role of autocrine factors produced by aiway basal cells in a 3D Organoid model testing bronchosphere generation which resembles epithelial remodeling processes in IPF. , 2019, , .		0
142	Close correlation between cumulative corticosteroid dose and weight gain in a German cohort of sarcoid patients. , 2019, , .		0
143	Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease. , 2020, , .		0
144	Temporal subtraction of serial CT scans for visualisation and quantification of disease progression in Idiopathic Pulmonary Fibrosis. , 2020, , .		0

#	Article	IF	Citations
145	Therapie der Lungenfibrosen: InterdisziplinÃre Diagnostik bessert Therapiechancen. , 0, , .		0